ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.28
-0.29 (-4.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.57
Open6.50
Bid6.00 x 1000
Ask6.59 x 800
Day's Range6.25 - 6.59
52 Week Range5.59 - 15.14
Volume269,795
Avg. Volume431,854
Market Cap110.678M
Beta4.43
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.67
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Zynerba Pharmaceuticals Inc Earnings Call

  • The Worst-Performing Marijuana Stocks in July
    Motley Fool9 days ago

    The Worst-Performing Marijuana Stocks in July

    Talk about buzzkills! These five pot stocks all fell by at least 19% last month.

  • Associated Press16 days ago

    Zynerba: 2Q Earnings Snapshot

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 89 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire16 days ago

    Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

    DEVON, Pa., Aug. 02, 2018-- Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today ...

  • GlobeNewswire17 days ago

    Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Financial Officer, Jim Fickenscher will present a company overview at the 38th Annual Canaccord Genuity Growth Conference on August 8, 2018 at 4:00 PM EDT at the InterContinental Boston. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire18 days ago

    Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update

    DEVON, Pa., July 31, 2018-- Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will host ...

  • ACCESSWIRE24 days ago

    This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up

    CNS disorders are seeing renewed interest from investors, and epilepsy has seen a particular resurgence in investor activity as numerous public companies have found success with new drugs and mechanisms. A little-known company called NeuroOne Medical (NMTC) is making strides with an all-new thin-film electrode technology, which comes from the labs of the Mayo Clinic. This prestigious institute is also a 10% stockholder in newly public NMTC.

  • InvestorPlace25 days ago

    Market Roasts Shares of Zynerba Pharmaceuticals

    Just as shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) were on the way to rebounding back to the $10 level, the stock fell on Friday after the company announced a share issuance. With a 25-percent cut in the ZYNE share price, is the sell-off in this micro-cap biotechnology firm overdone? Zynerba announced a tiny, $32.5 million public offering of its shares: 4.062 million shares at $8 each.

  • Main Line synthetic cannabinoid developer seeking $32.5M from stock sale
    American City Business Journals29 days ago

    Main Line synthetic cannabinoid developer seeking $32.5M from stock sale

    The proceeds will be used to advance then company's experimental treatment for Fragile X Syndrome.

  • Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
    MarketWatch29 days ago

    Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks

    Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.

  • GlobeNewswire29 days ago

    Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Zynerba Pharmaceuticals, Inc. (ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Zynerba has granted the underwriters a 30-day option to purchase up to 609,375 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as the sole book-running manager.

  • Benzinga29 days ago

    Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 19) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Champions Oncology ...

  • GlobeNewswirelast month

    Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Zynerba Pharmaceuticals, Inc. (ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by Zynerba.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Zynerba intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as the sole book-running manager.

  • GlobeNewswirelast month

    Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

    -Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002-- Presentation Today at the 16 th NFXF International Fragile X Conference-. ...

  • GlobeNewswirelast month

    Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome

    DEVON, Pa., July 09, 2018 (GLOBE NEWSWIRE) --  Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the initiation of a multi-national, randomized, double blind placebo controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX). The CONNECT-FX trial will evaluate the efficacy and safety of ZYN002 (CBD Gel) in children ages three to 17 with full mutation Fragile X syndrome (FXS). FXS is a genetic condition that causes intellectual disability, behavioral and learning challenges and is the most common known single gene cause of autism spectrum disorder.

  • MarketWatchlast month

    Zynerba stock rebounds after selloff driven by failed cannabis-based skin patch trial

    Shares of Zynerba Pharmaceuticals Inc. rose 7% in Friday trade, recouping some of their prior-session losses that came after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. Zynerba(ZYNE) , which is developing cannabis-based therapies for rare neurospsychiatric disorders, said the trial of ZYN001, which delivers tetrahydrocannabinol (THC) through a transdermal patch, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC in healthy volunteers. THC is the psychoactive ingredient in cannabis and the company was trying to find a way to deliver it without patients having to take it orally, which can make them high.

  • Benzingalast month

    HC Wainwright Unfazed By Zynerba Ending ZYN001: Drug 'Wasn't In Our Numbers'

    Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) stock plummeted 17.8 percent at Thursday’s open after the company ended a Phase 1 study for ZYN001, a tetrahydrocannabinol patch. While there were no adverse ...

  • Benzingalast month

    Zynerba Redirects Resources After ZYN001 Study Fails To Meet Top-Line Results

    Although the pro-drug of tetrahydrocannabinol was “very well tolerated” by the skin and no adverse events were reported, Zynerba is terminating the study. It will instead focus its time and resources on ZYN002 for Fragile X syndrome, developmental and epileptic encephalopathy and adult refractory epilepsy. ZYN002 will begin a pivotal study of ZYN002 in Fragile X in “mid-year 2018” and continue Phase 2 trials for the other two indications.

  • MarketWatchlast month

    Zynerba shares slide 17% after trial of cannabis-based skin patch fails to meet goals

    Shares of Zynerba Pharmaceuticals Inc. (zyne) slid about 17% in premarket trade Thursday, after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. The company, which is developing cannabis-based therapies for rare neruospsychiatric disorders, said the trial of ZYN001, a patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC. "This Phase 1 study was a single and multiple dose, placebo-controlled first-in-man study to assess the safety and pharmacokinetics of ZYN001 administered as a transdermal patch to healthy adult subjects," Zynerba said in a statement.

  • GlobeNewswirelast month

    Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying ZYN001, the Company’s patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers. As a result of these data, the Company will focus its development efforts and investments on the ZYN002 Fragile X syndrome, developmental and epileptic encephalopathy (DEE) and adult refractory epilepsy programs. The Company expects that this change will extend its cash runway into the second half of 2019.

  • TheStreet.com2 months ago

    FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

    approaching the U.S launch of its long-awaited Epidiolex epilepsy medicine, the space for cannabis-based drugs to treat the disorder and other maladies is finally moving into reality. London-based GW Pharma said Monday (June 25) the U.S. Food and Drug Administration (FDA) has approved Epidiolex, a cannabinoid-based oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome -- both rare forms of epilepsy -- in patients at least two years old.

  • Benzinga2 months ago

    GW Pharma's Epidiolex Becomes First Cannabis-Based FDA-Approved Drug

    The drug is derived from the cannabidiol of cannabis, and, as the plant is yet to be decriminalized by federal regulators, its approval gives GW Pharma a lead among cannabis-exposed companies in the U.S. financial markets. The FDA seal is nonetheless seen to be a boon for the broader industry. “It makes it harder for Congress to continue to list cannabis as a Schedule I controlled substance,” Debra Borchardt, CEO at cannabis-focused financial media outlet Green Market Report, told Benzinga in April.

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Jefferies 2018 Global Healthcare Conference on Thursday June 7, 2018 at 10:30 AM EDT at the Grand Hyatt hotel in New York, NY. Zynerba Pharmaceuticals (ZYNE) is a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders with high unmet medical needs.

  • The Tech Revolutionizing The Billion Dollar Marijuana Business
    Oilprice.com3 months ago

    The Tech Revolutionizing The Billion Dollar Marijuana Business

    Reefer madness is reaching a full-blown frenzy, with total legal worldwide marijuana sales expected to surpass $63 billion in less than ten years. And now the tech behind bitcoin is poised to take the cannabis boom to the next level

  • Investopedia3 months ago

    Pot Stock Winners of the Week

    Here are the week's four biggest marijuana stock winners.